Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Receivables (2021 - 2025)

Historic Change in Receivables for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$159977.0.

  • InMed Pharmaceuticals' Change in Receivables fell 60645.62% to -$159977.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$77178.0, marking a year-over-year increase of 3002.9%. This contributed to the annual value of $114690.0 for FY2025, which is 2407.1% up from last year.
  • According to the latest figures from Q4 2025, InMed Pharmaceuticals' Change in Receivables is -$159977.0, which was down 60645.62% from -$122160.0 recorded in Q3 2025.
  • InMed Pharmaceuticals' 5-year Change in Receivables high stood at $207019.0 for Q4 2023, and its period low was -$165188.0 during Q1 2024.
  • In the last 5 years, InMed Pharmaceuticals' Change in Receivables had a median value of $10198.0 in 2021 and averaged $10230.4.
  • Examining YoY changes over the last 5 years, InMed Pharmaceuticals' Change in Receivables showed a top increase of 1445156.74% in 2022 and a maximum decrease of 259257.61% in 2022.
  • Over the past 5 years, InMed Pharmaceuticals' Change in Receivables (Quarter) stood at -$638.0 in 2021, then surged by 14451.57% to $91563.0 in 2022, then soared by 126.09% to $207019.0 in 2023, then plummeted by 110.94% to -$22645.0 in 2024, then plummeted by 606.46% to -$159977.0 in 2025.
  • Its Change in Receivables was -$159977.0 in Q4 2025, compared to -$122160.0 in Q3 2025 and $99715.0 in Q2 2025.